Celebrities Paint Masks for Mesothelioma Fundraising Event

The goal of the Pacific Mesothelioma Center is to be the most innovative nonprofit research and cancer treatment organization in the world. Its latest fundraising event is a perfect example. As part of the Pacific Heart, Lung &Blood Institute, the Pacific Mesothelioma Center will play a major role in the unMASKing the Cure for Cancer Gala, an innovative fundraising idea once used by Prince Charles more than 20 years ago. The November 21 event, held at the UCLA Luskin Conference Center, includes the auctioning of eclectic masks that were hand-painted by various celebrities, including actors, artists, athletes and musicians. The goal is to raise more than $200,000 for the research of mesothelioma and other cancers. The Pacific Heart, Lung &Blood Institute has been doing a myriad of fundraising events the last two decades, but never anything like this. Mark Hamill, Dwayne Johnson Among Contributors The event will include live and silent auctions of more than 25 celebrity-painted masks. Many were invited to contribute by actor Jamie Foxx, an early supporter of the cause. Celebrity painters for the unMASKing the Cure for Cancer Gala include: Mark Hamill (actor; “Star Wars” films) Sir Anthony Hopkins (actor and director; “Silence of the Lambs”) Dwayne “The Rock” Johnson (wrestler and actor; “Jumanji: Welcome to the Jungle”) Eileen Davidson (actress, “Days of Our Lives”) Sugar Ray Leonard (former ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

CONCLUSION: With the increased use of immunotherapeutic agents, increased awareness and early recognition are required for effective management of irAEs. Our experience as a single institution might be of use for health care providers in oncology. PMID: 32935638 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
Authors: Wan S, Zhao H Abstract The present study aimed to explore the diagnostic and prognostic value of lncRNA maternally expressed 3 (MEG3) in cervical cancer. Eighty-four patients with cervical cancer from February 2013 to March 2014 were enrolled in the observation group (OG), and another 58 female subjects who underwent physical examination at Huangshi Central Hospital were enrolled as the control group (CG). The serum MEG3 expression of patients in the two groups was detected by RT-qPCR, and the ability of MEG3 to aid in the diagnosis of cervical cancer, lymph node metastasis and FIGO staging, as well as to ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
In conclusion, SLC17A9 can be used as a new molecular marker to predict the poor prognosis of patients with HCC. PMID: 32934749 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
In conclusion, the present study revealed that linalool inhibits T-ALL cell survival with involvement of the MAPK signaling pathway. JNK activation and ERK inhibition may play a functional role in apoptosis induction of T-ALL cells. Linalool may be developed as a novel anti T-ALL agent. PMID: 32934748 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
In conclusion, psychological stress was more prominent in younger patients with stage IV breast cancer treated with hormonal therapy compared with elderly patients. Importantly, improving QOL within the 3 months after treatment initiation could lead to longer PFS rate. PMID: 32934747 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Verma A, Najahi-Missaoui W, Cummings BS, Somanath PR Abstract Metastatic prostate cancer (PCa) has a very high mortality rate in men, in Western countries and lacks reliable treatment. The advanced-stage PCa cells overexpress P21 (RAC1) activated kinase-1 (PAK1) and secreted phospholipase A2 (sPLA2) suggesting the potential utility of pharmacologically targeting these molecules to treat metastatic PCa. The small molecule, inhibitor targeting PAK1 activation-3 (IPA3) is a highly specific allosteric inhibitor of PAK1; however, it is metabolically unstable once in the plasma thus, limiting its utility as a ch...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Conclusion: In addition to asbestos-related mortality in occupational exposure groups, this initial follow-up of this cohort also shows elevated mortality for some asbestos-related causes in non-occupational exposure groups.
Source: Journal of Occupational and Environmental Medicine - Category: Occupational Health Tags: ORIGINAL ARTICLE Source Type: research
Abstract In an editorial in an earlier issue of this journal, Johanson &Tinnerberg (1) expressed serious and well-founded concern over the large number of future occupational cancer cases that will result if exposures for a number of substances are not reduced below the so-called "binding occupational exposure limit values" (BOELV) issued by the EU (2). The balance between what is perceived as possible to comply with and the foreseeable health gain when setting BOELV is further discussed in a letter to the Editor by Cherrie (3). This debate raises several important aspects of how to protect workers f...
Source: Scandinavian Journal of Work, Environment and Health - Category: Occupational Health Authors: Tags: Scand J Work Environ Health Source Type: research
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Thoracic surgeon Dr. Robert Cameron and the Pacific Mesothelioma Center moved closer to a major treatment advance by obtaining U.S. patent approval for their novel mesenchymal stem cell research program. The patent approval in February makes the research program more attractive to potential investors who could accelerate development and change the way malignant mesothelioma is treated. “This is a big deal in the developmental path for MSC [mesenchymal stem cell] therapy,” Patent Adviser Dr. Walid Sabbagh told The Mesothelioma Center at Asbestos.com. “The patent is a pathway to really help these cancer pat...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Autoimmune Disease | Cancer | Cancer & Oncology | Cardiology | Cardiovascular & Thoracic Surgery | Chemotherapy | Conferences | Environmental Health | Fundraising | Genetics | Heart | Lung Cancer | Mesothelioma | Stem Cell Therapy | Stem Cells | Sugar